HIV protease inhibitors: a review of molecular selectivity and toxicity

References

• UNAIDSGlobal Report: UNAIDS Report on the Global AIDS Epidemic 2010GenevaUNAIDS2010
   Google Scholar
• RiddlerSAHaubrichRDiRienzoAGAIDS Clinical Trials Group Study A5142 TeamClass-sparing regimens for initial treatment of HIV-1 infectionN Engl J Med2008358202095210618480202
   PubMed Web of Science ®Google Scholar
• BozzetteSAAkeCFTamHKChangSWLouisTACardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infectionN Engl J Med2003348870271012594314
   PubMed Web of Science ®Google Scholar
• HruzPWHIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer modelsCurr Opin HIV AIDS20083666066519373039
   PubMed Web of Science ®Google Scholar
• KotlerDPHIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patientsJ Acquir Immune Defic Syndr200849Suppl 2S79S8518725816
   PubMed Web of Science ®Google Scholar
• SoontornniyomkijVUmlaufAChungSAHIV protease inhibitor exposure predicts cerebral small vessel diseaseAIDS20142891297130624637542
   PubMed Web of Science ®Google Scholar
• CameronDWda SilvaBAArribasJRA 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapyJ Infect Dis2008198223424018540803
   PubMed Web of Science ®Google Scholar
• KoltaSFlandrePVanPNFat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trialCurr HIV Res201191313921198431
   PubMed Web of Science ®Google Scholar
• PatonNIKityoCHoppeAEARNEST Trial TeamAssessment of second-line antiretroviral regimens for HIV therapy in AfricaN Engl J Med2014371323424725014688
   PubMed Web of Science ®Google Scholar
• KrohnARedshawSRitchieJCGravesBJHatadaMHNovel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostereJ Med Chem19913411334033421956054
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationRoche, Fortovase^® (saquinavir)Silver Spring, MDUS Food and Drug Administration2003 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20828s015ppi.pdfAccessed March 25, 2015
   Google Scholar
• WellerIVWilliamsIGABC of AIDS. Antiretroviral drugsBMJ200132272991410141211397751
   PubMed Web of Science ®Google Scholar
• CameronDWJapourAJXuYRitonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS199913221322410202827
   PubMed Web of Science ®Google Scholar
• González de RequenaDGallegoOde MendozaCCorralAJiménez-NácherISorianoVIndinavir plasma concentrations and resistance mutations in patients experiencing early virological failureAIDS Res Hum Retroviruses200319645745912882654
   PubMed Web of Science ®Google Scholar
• HreskoRCHruzPWHIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4PLoS One201169e2523721966466
   PubMed Web of Science ®Google Scholar
• VirabenRAquilinaCIndinavir-associated lipodystrophyAIDS1998126F37F399583592
   PubMed Web of Science ®Google Scholar
• KempfDJMarshKCKumarGPharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirAntimicrob Agents Chemother19974136546609056009
   PubMed Web of Science ®Google Scholar
• ZeldinRKPetruschkeRAPharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJ Antimicrob Chemother20045314914657084
   PubMed Web of Science ®Google Scholar
• López AspirozECabrera FigueroaSEIglesias GómezAValverde MerinoMPDomínguez-Gil HurléACYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant womanClin Drug Investig20153516166
   Web of Science ®Google Scholar
• PurnellJQZambonAKnoppRHEffect of ritonavir on lipids and post-heparin lipase activities in normal subjectsAIDS2000141515710714567
   PubMed Web of Science ®Google Scholar
• MaxBShererRManagement of the adverse effects of antiretroviral therapy and medication adherenceClin Infect Dis200030Suppl 2S96S11610860894
   PubMed Web of Science ®Google Scholar
• ShamHLKempfDJMollaAABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseAntimicrob Agents Chemother19984212321832249835517
   PubMed Web of Science ®Google Scholar
• NoorMAParkerRAO’MaraEThe effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adultsAIDS200418162137214415577646
   PubMed Web of Science ®Google Scholar
• ManfrediRSabbataniSSerious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney functionAIDS200620182399240017117031
   PubMed Web of Science ®Google Scholar
• CresswellFVTomlinsJChurchillDRWalker-BoneKRichardsonDAchilles tendinopathy following Kaletra (lopinavir/ritonavir) useInt J STD AIDS2014251183383524516081
   PubMed Web of Science ®Google Scholar
• St ClairMHMillardJRooneyJIn vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agentsAntiviral Res199629153568721545
   PubMed Web of Science ®Google Scholar
• TieYWangYFBorossPICritical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitorsProtein Sci201221333935022238126
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJrKLEAN study teamThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet2006368953447648216890834
   PubMed Web of Science ®Google Scholar
• GatheJCWoodRSanneILong-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on studyClin Ther200628574575416861096
   PubMed Web of Science ®Google Scholar
• JuddADuongTGalliLEuropean Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoordPost-licensing safety of fosamprenavir in HIV-infected children in EuropePharmacoepidemiol Drug Saf201423332132524741696
   PubMed Web of Science ®Google Scholar
• BeckerSAAtazanavir: improving the HIV protease inhibitor classExpert Rev Anti Infect Ther20031340341315482137
   PubMedGoogle Scholar
• SquiresKLazzarinAGatellJMComparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVJ Acquir Immune Defic Syndr20043651011101915247553
   PubMed Web of Science ®Google Scholar
• MurphyRLSanneICahnPDose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsAIDS200317182603261414685054
   PubMed Web of Science ®Google Scholar
• CahnPEGatellJMSquiresKAtazanavir – a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trialsJ Int Assoc Physicians AIDS Care (Chic)200433929815573713
   PubMedGoogle Scholar
• DauchyFALawson-AyayiSde La FailleRIncreased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapyKidney Int201180330230921544066
   PubMed Web of Science ®Google Scholar
• CalzaLTrapaniFSalvadoriCIncidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirScand J Infect Dis201345214715422991923
   PubMed Web of Science ®Google Scholar
• RusconiSLa Seta CatamancioSCitterioPSusceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitorsAntimicrob Agents Chemother20004451328133210770770
   PubMed Web of Science ®Google Scholar
• LarderBAHertogsKBloorSTipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesAIDS200014131943194810997398
   PubMed Web of Science ®Google Scholar
• OrmanJSPerryCMTipranavir: a review of its use in the management of HIV infectionDrugs200868101435146318578560
   PubMed Web of Science ®Google Scholar
• LefebvreESchifferCAResilience to resistance of HIV-1 protease inhibitors: profile of darunavirAIDS Rev200810313114218820715
   PubMed Web of Science ®Google Scholar
• TieYBorossPIWangYFHigh resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strainsJ Mol Biol2004338234135215066436
   PubMed Web of Science ®Google Scholar
• BrowerETBachaUMKawasakiYFreireEInhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical useChem Biol Drug Des200871429830518312292
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsWashington, DCDepartment of Health and Human Services2011
   Google Scholar
• MolinaJMCohenCKatlamaCTMC114-C208 Study Group; TMC114-C215 Study GroupSafety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 2 4-week results of POWER 3J Acquir Immune Defic Syndr2007461243117621237
   PubMed Web of Science ®Google Scholar
• ShamHLZhaoCLiLNovel lopinavir analogues incorporating non-Aromatic P-1 side chains – synthesis and structure – activity relationshipsBioorg Med Chem Lett200212213101310312372511
   PubMed Web of Science ®Google Scholar
• Ya nQHruzPWDirect comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposalJ Acquir Immune Defic Syndr200540439840316280693
   PubMed Web of Science ®Google Scholar
• HeGXYangZYWilliamsMDiscovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profileMed Chem Commun201121110931098
   Web of Science ®Google Scholar
• HruzPWYanQTsaiLGS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model systemAntimicrob Agents Chemother20115541377138221245443
   PubMed Web of Science ®Google Scholar
• Prabu-JeyabalanMKingNMNalivaikaEAHeilek-SnyderGCammackNSchifferCASubstrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 proteaseAntimicrob Agents Chemother20065041518152116569872
   PubMed Web of Science ®Google Scholar
• AlaPJDeLoskeyRJHustonEEMolecular recognition of cyclic urea HIV-1 protease inhibitorsJ Biol Chem19982732012325123319575185
   PubMed Web of Science ®Google Scholar
• HoffmannCART 2 010/2011: The horizon and beyondHoffmannCRockstrohJKHIV 2010 – A TextbookHamburgMedizin Fokus Verlag2010127159
   Google Scholar
• Concert PharmaceuticalsPharmacokinetics, safety and tolerability of isotopologs of atazanavir (ATV), with pharmacokinetic comparison to reyataz Available from: http://clinicaltrials.gov/ct2/show/NCT01458769?term=CTP-518&rank=1. NLM identifier: NCT01458769Accessed March 5, 2015
   Google Scholar
• HollandAWynneBRuffDGuttendorfRA first in human study evaluating the safety, tolerability, and pharmacokinetics (PK) of SPI-256, a novel HIV protease inhibitor (PI), administered alone and in combination with ritonavir (RTV) in healthy adult subjectsPoster presented at the 48th Annual ICAAC/46th Annual IDSA MeetingOctober 25–28, 2008Washington, DC
   Google Scholar
• GulnikSVEissenstatMApproaches to the design of HIV protease inhibitors with improved resistance profilesCurr Opin HIV AIDS20083663364119373035
   PubMed Web of Science ®Google Scholar
• GulnikSEissenstatMAfoninaEPreclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer (PKE)Presented at the 16th CROI Conference on Retroviruses and Opportunistic InfectionsFebruary 8–12, 2009Montreal, Qc
   Google Scholar
• NolanDMetabolic complications associated with HIV protease inhibitor therapyDrugs200363232555257414636077
   PubMed Web of Science ®Google Scholar
• ZhouHGurleyECJarujaronSHIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytesAm J Physiol Gastrointest Liver Physiol20062916G1071G108016861219
   PubMed Web of Science ®Google Scholar
• KimJBSarrafPWrightMNutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1J Clin Invest19981011199421459
   PubMed Web of Science ®Google Scholar
• FajasLSchoonjansKGelmanLRegulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolismMol Cell Biol19991985495550310409739
   PubMed Web of Science ®Google Scholar
• SatoRYangJWangXAssignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1)J Biol Chem19942692517267172738006035
   PubMed Web of Science ®Google Scholar
• SakaiJRawsonRBEspenshadePJMolecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cellsMol Cell1998245055149809072
   PubMed Web of Science ®Google Scholar
• WangXPaiJTWiedenfeldEAPurification of an interleukin-1 beta converting enzyme-related cysteine protease that cleaves sterol regulatory element-binding proteins between the leucine zipper and transmembrane domainsJ Biol Chem19952703018044180507629113
   PubMed Web of Science ®Google Scholar
• PaiJTBrownMSGoldsteinJLPurification and cDNA cloning of a second apoptosis-related cysteine protease that cleaves and activates sterol regulatory element binding proteinsProc Natl Acad Sci U S A19969311543754428643593
   PubMed Web of Science ®Google Scholar
• HiranoYYoshidaMShimizuMSatoRDirect demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathwayJ Biol Chem200127639364313643711477106
   PubMed Web of Science ®Google Scholar
• CaronMAuclairMVigourouxCGlorianMForestCCapeauJThe HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistanceDiabetes20015061378138811375339
   PubMed Web of Science ®Google Scholar
• GuanMFousekKChowWANelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancerFEBS J2012279132399241122540830
   PubMed Web of Science ®Google Scholar
• TranHRobinsonSMikhailenkoIStricklandDKModulation of the LDL receptor and LRP levels by HIV protease inhibitorsJ Lipid Res200344101859186912837856
   PubMed Web of Science ®Google Scholar
• BastardJPCaronMVidalHAssociation between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistanceLancet200235993111026103111937183
   PubMed Web of Science ®Google Scholar
• RahmouniKSigmundCDId3, E47, and SREBP-1c: fat factors controlling adiponectin expressionCirc Res2008103656556718796641
   PubMed Web of Science ®Google Scholar
• XuAYinSWongLChanKWLamKSAdiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in miceEndocrinology2004145248749414592951
   PubMed Web of Science ®Google Scholar
• PeppingJKOtvosLSurmaczEGuptaSKellerJNBruce-KellerAJDesigner adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitorsJ Neuroimmune Pharmacol20149338839824562631
   PubMed Web of Science ®Google Scholar
• MurataHHruzPWMuecklerMThe mechanism of insulin resistance caused by HIV protease inhibitor therapyJ Biol Chem200027527202512025410806189
   PubMed Web of Science ®Google Scholar
• MurataHHruzPWMuecklerMIndinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrationsAIDS200216685986311919487
   PubMed Web of Science ®Google Scholar
• HertelJStruthersHHorjCBHruzPWA structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activityJ Biol Chem200427953551475515215496402
   PubMed Web of Science ®Google Scholar
• AndréPGroettrupMKlenermanPAn inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responsesProc Natl Acad Sci U S A1998952213120131249789051
   PubMed Web of Science ®Google Scholar
• PajonkFHimmelsbachJRiessKSommerAMcBrideWHThe human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cellsCancer Res200262185230523512234989
   PubMed Web of Science ®Google Scholar
• HamelFGFawcettJTsuiBTBennettRGDuckworthWCEffect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cellsDiabetes Obes Metab20068666166817026490
   PubMed Web of Science ®Google Scholar
• LiangJSDistlerOCooperDAHIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemiaNat Med20017121327133111726973
   PubMed Web of Science ®Google Scholar
• SteinbergDCarewTEFieldingCLipoproteins and the pathogenesis of atherosclerosisCirculation19898037197232670321
   PubMed Web of Science ®Google Scholar
• De BarrosSZakaroff-GirardALafontanMGalitzkyJBourlierVInhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9J Pharmacol Exp Ther2007320129129917038510
   PubMed Web of Science ®Google Scholar
• ParkerRAFlintOPMulveyREndoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitorsMol Pharmacol20056761909191915755908
   PubMed Web of Science ®Google Scholar
• MulliganKGrunfeldCTaiVWHyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infectionJ Acquir Immune Defic Syndr2000231354310708054
   PubMed Web of Science ®Google Scholar
• GillsJJLopiccoloJTsurutaniJNelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoClin Cancer Res200713175183519417785575
   PubMed Web of Science ®Google Scholar
• CapelEAuclairMCaron-DebarleMCapeauJEffects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytesAntivir Ther201217354955622293506
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI)Nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors Available from: https://clinicaltrials.gov/ct2/show/NCT00436735. NLM identifier: NCT00436735Accessed March 25, 2015
   Google Scholar
• InoueTShirakiKFukeHProteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathwayAnticancer Drugs200617326126816520654
   PubMed Web of Science ®Google Scholar
• YorimitsuTNairUYangZKlionskyDJEndoplasmic reticulum stress triggers autophagyJ Biol Chem200628140302993030416901900
   PubMed Web of Science ®Google Scholar
• RocheDGreinerJAubertinAMVierlingPSynthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitorsEur J Med Chem20084371506151817950955
   PubMed Web of Science ®Google Scholar